EUVIMEDEUVIMED entdecken
Crossref

First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia

Jie Zang, Hongfei Cheng, Yang Luo, Wenbin Jin, Yuxin Lai, Qingming Zheng, Yumeng Peng, Hank F Kung, Lin Zhu, Chunlin Ke, Chen Liu, Weibing Miao iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-03 · 53 (4) · 2530-2539

DOI: 10.1007/s00259-025-07625-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 31.10.2025. Verfasst von Jie Zang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Binhai Campus of the First Affiliated Hospital, National Regional Medical Center, Fujian Medical University, Fujian P…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Organometallic Compounds, Nitroimidazoles, Gelatinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: the Innovation of Science and Technology of Fujian Province, Fujian Medical University Undergraduate Innovation and Entrepreneurship Training Program Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Preclinical studies have demonstrated that [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04, a bivalent agent containing an extra hypoxia-sensitive 2-nitroimidazole (NI) group, exhibited favorable tumor binding affinity and improved tumor uptake and retention than [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-04. This study aims to further investigate the value of clinical application for [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT via a direct head-to-head comparison with [68Ga]Ga-DOTA-FAPI-04. METHODS: A total of 50 patients underwent paired [68Ga]Ga-DOTA-NI-FAPI-04 and [68Ga]Ga-DOTA-FAPI-04 PET/CT within 1 week interval. Among these, four patients underwent serial dynamic [68Ga]Ga-DOTA-NI-FAPI-04 PET scans for dosimetry evaluation, and the others underwent scans at 60 min and 120 min. Additionally, we calculated the SUVmax differences (ΔSUVmax) by [68Ga]Ga-DOTA-NI-FAPI-04 minus [68Ga]Ga-DOTA-FAPI-04 PET/CT for further analysis. Immunohistochemistry for FAP and hypoxia-inducible factor-1 alpha (HIF-1α) was performed in 22 primary tumors. RESULTS: The effective absorbed dose of [68Ga]Ga-DOTA-NI-FAPI-04 PET/CT was calculated as 1.95E-02 mSv/MBq. Tumor uptake of [68Ga]Ga-DOTA-NI-FAPI-04 showed rapid uptake and steady values (average SUVmax 11.6-13.0 from 3 to 120 min). [68Ga]Ga-DOTA-NI-FAPI-04 exhibited significantly higher uptake in tumor lesions compared to [68Ga]Ga-DOTA-FAPI-04 PET/CT, particularly in primary tumors (P < 0.05), nodal metastases (P < 0.001), bone metastases (P < 0.001), and liver metastases (P < 0.05). That of FAP expression was correlated with that of HIF-1α (r = 0.661, P < 0.001), and the expression of HIF-1α showed a positive correlation with ΔSUVmax (r = 0.528, P = 0.011). CONCLUSION: [68Ga]Ga-DOTA-NI-FAPI-04 showed significantly higher tumor uptake and retention over [68Ga]Ga-DOTA-FAPI-04, with particularly enhanced visualization of hypoxic lesions, suggesting that hypoxia-sensitive moiety may play an important role in detection of tumors. Further study of [177Lu]Lu-DOTA-NI-FAPI-04 in humans is warranted to explore its clinical applications. URL OF REGISTRY: https://clinicaltrials.gov/study/NCT06688305 . TRIAL REGISTRATION: ClinicalTrials.gov, NCT06688305, Registered 14 November 2024, retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyOrganometallic CompoundsNitroimidazolesGelatinasesSerine EndopeptidasesMembrane ProteinsTumor HypoxiaRadiopharmaceuticalsHumansFemaleMaleMiddle AgedAgedGallium RadioisotopesAdultEndopeptidasesCoordination Complexes

Stichwörter der Autor:innen

FAPIHypoxiaNitroimidazolePET/CT

Substanzen

Gallium RadioisotopesOrganometallic CompoundsNitroimidazolesGelatinasesEndopeptidasesSerine EndopeptidasesMembrane ProteinsCoordination ComplexesRadiopharmaceuticalsGallium-68

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Binhai Campus of the First Affiliated Hospital, National Regional Medical Center, Fujian Medical University, Fujian Province, Fuzhou, 350212, China.
  • Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fujian Province, Fuzhou, 350005, China.
  • College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
  • School of Medical Imaging, Fujian Medical University, Fujian Province, Fuzhou, 350122, China.
  • Department of Radiology, University of Pennsylvania, PA, Philadelphia, 19104, USA.
  • Department of Radiotherapy, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fujian Province, Fuzhou, 350005, China. 296200383@fjmu.edu.cn.

ORCID-Profile: Weibing Miao

Förderung

  • the Innovation of Science and Technology of Fujian Province
  • Fujian Medical University Undergraduate Innovation and Entrepreneurship Training Program Project
  • National Natural Science Foundation of China
  • Fujian Provincial Clinical Key Specialty Construction Project

Zitieren

APA

Zang, J., Cheng, H., Luo, Y., Jin, W., Lai, Y., Zheng, Q., Peng, Y., Kung, H. F., Zhu, L., Ke, C., Liu, C., & Miao, W. (2026). First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia. European Journal of Nuclear Medicine and Molecular Imaging, 53(4), 2530-2539. https://doi.org/10.1007/s00259-025-07625-0

Vancouver

Zang J, Cheng H, Luo Y, Jin W, Lai Y, Zheng Q, et al. First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(4):2530-2539. doi:10.1007/s00259-025-07625-0

BibTeX
@article{Zang2026,
  author = {Zang, Jie and Cheng, Hongfei and Luo, Yang and Jin, Wenbin and Lai, Yuxin and Zheng, Qingming and Peng, Yumeng and Kung, Hank F and Zhu, Lin and Ke, Chunlin and Liu, Chen and Miao, Weibing},
  title = {First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {4},
  pages = {2530--2539},
  doi = {10.1007/s00259-025-07625-0}
}
Kostenlos starten →